Prostate cancer is the most common non-skin cancer in American men. The current methods of screening for prostate cancer, which include digital rectal examinations (DREs) and serum levels of prostate specific antigen (PSA), do not detect many prostate tumors including some which are high grade and aggressive. In an effort to find better biomarkers for prostate cancer detect and prognosis. The San Antonio Center for Biomarkers of Risk of prostate cancer and genitourinary cancers (SABOR) was established in 2001. SABOR has gathered a population-based, minority-rich, cohort with extensive clinical data and biospecimens while tracking cancer-related outcomes. This cohort has been utilized for the discovery and validation of numerous new biomarkers for prostate cancer. Furthermore, specimens have been gathered for studies of bladder and kidney cancers that have been utilized by EDRN collaborators in biomarker discovery. In addition to these efforts, substantial progress has been made in the development and enhancement of the EDRN-PCPT Prostate Cancer Risk Calculator. The Risk Calculator uses numerous variables and biomarkers in addition to PSA and DRE to predict a man's risk of prostate cancer and, if detected, the chance of high-grade disease. In this current proposal, 3 specific aims are proposed: 1) We will conduct validation studies on promising serum-based biomarkers of prostate cancer;2) We will conduct validation studies of genomic markers of prostate cancer prognosis;3) We will employ results from our validation studies as well as EDRN-wide and other well-conducted validation studies to expand the applicability of the Prostate Cancer Risk Calculator, leading to individualized patient risk assessment. In support of these validation studies, the SABOR cohort will continue to be followed and additional biologies will be gathered on prostate cancer patients with long-term outcome data. In addition, the SABOR scientific personnel will continue to conduct EDRN Network validation studies, serve in leadership positions within the Network, and assist the EDRN with the design, conduct, and analysis of early detection validation studies that will alter the standard of care practice in the United States.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA086402-14
Application #
8511578
Study Section
Special Emphasis Panel (ZCA1-SRLB-3 (M1))
Program Officer
Kagan, Jacob
Project Start
2000-05-15
Project End
2015-06-30
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
14
Fiscal Year
2013
Total Cost
$651,340
Indirect Cost
$215,661
Name
University of Texas Health Science Center San Antonio
Department
Urology
Type
Schools of Medicine
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Shi, Tujin; Quek, Sue-Ing; Gao, Yuqian et al. (2017) Multiplexed targeted mass spectrometry assays for prostate cancer-associated urinary proteins. Oncotarget 8:101887-101898
Long Parma, Dorothy; Muñoz, Edgar; Ogden, Susan M et al. (2017) Helicobacter Pylori Infection in Texas Hispanic and Non-Hispanic White Men: Implications for Gastric Cancer Risk Disparities. Am J Mens Health 11:1039-1045
Luebeck, E Georg; Curtius, Kit; Hazelton, William D et al. (2017) Identification of a key role of widespread epigenetic drift in Barrett's esophagus and esophageal adenocarcinoma. Clin Epigenetics 9:113
Macleod, Liam C; Ellis, William J; Newcomb, Lisa F et al. (2017) Timing of Adverse Prostate Cancer Reclassification on First Surveillance Biopsy: Results from the Canary Prostate Cancer Active Surveillance Study. J Urol 197:1026-1033
Ankerst, Donna Pauler; Gelfond, Jonathan; Goros, Martin et al. (2016) Serial Percent Free Prostate Specific Antigen in Combination with Prostate Specific Antigen for Population Based Early Detection of Prostate Cancer. J Urol 196:355-60
Chen, Haitao; Liu, Xu; Brendler, Charles B et al. (2016) Adding genetic risk score to family history identifies twice as many high-risk men for prostate cancer: Results from the prostate cancer prevention trial. Prostate 76:1120-9
Newcomb, Lisa F; Thompson Jr, Ian M; Boyer, Hilary D et al. (2016) Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort. J Urol 195:313-20
Wang, Yi-Wei; Ma, Xiaotu; Zhang, Yu-An et al. (2016) ITPKA Gene Body Methylation Regulates Gene Expression and Serves as an Early Diagnostic Marker in Lung and Other Cancers. J Thorac Oncol 11:1469-81
Wang, Yao; Jadhav, Rohit Ramakant; Liu, Joseph et al. (2016) Roles of Distal and Genic Methylation in the Development of Prostate Tumorigenesis Revealed by Genome-wide DNA Methylation Analysis. Sci Rep 6:22051
Liss, M A; Schenk, J M; Faino, A V et al. (2016) A diagnosis of prostate cancer and pursuit of active surveillance is not followed by weight loss: potential for a teachable moment. Prostate Cancer Prostatic Dis 19:390-394

Showing the most recent 10 out of 144 publications